{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:24:00Z","timestamp":1787185440674,"version":"build-2736575974"},"reference-count":66,"publisher":"SAGE Publications","issue":"9","license":[{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100016658","name":"Plan Nacional sobre Drogas","doi-asserted-by":"publisher","award":["2024I057"],"award-info":[{"award-number":["2024I057"]}],"id":[{"id":"10.13039\/100016658","id-type":"DOI","asserted-by":"publisher"}]},{"name":"European Union Home Affairs Funds","award":["101045825"],"award-info":[{"award-number":["101045825"]}]},{"DOI":"10.13039\/501100002809","name":"Generalitat de Catalunya","doi-asserted-by":"publisher","award":["2021SGR00520"],"award-info":[{"award-number":["2021SGR00520"]}],"id":[{"id":"10.13039\/501100002809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002809","name":"Generalitat de Catalunya","doi-asserted-by":"publisher","award":["2021SGR0090"],"award-info":[{"award-number":["2021SGR0090"]}],"id":[{"id":"10.13039\/501100002809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002809","name":"Generalitat de Catalunya","doi-asserted-by":"publisher","award":["2022 FISDU 00004"],"award-info":[{"award-number":["2022 FISDU 00004"]}],"id":[{"id":"10.13039\/501100002809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011033","name":"agencia estatal de investigaci\u00f3n","doi-asserted-by":"publisher","award":["PID2022-137541OB-I00"],"award-info":[{"award-number":["PID2022-137541OB-I00"]}],"id":[{"id":"10.13039\/501100011033","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Psychopharmacol"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The continual emergence of novel synthetic cathinones poses significant public health concerns due to their unpredictable pharmacological profiles and potential for abuse. Among these, 4-F-3-Me-\u03b1-PVP\u2014a newly identified analogue of \u03b1-PVP\u2014has recently surfaced on the illicit drug market, yet its biological effects remain uncharacterized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim:<\/jats:title>\n                    <jats:p>To provide the first comprehensive pharmacological evaluation of 4-F-3-Me-\u03b1-PVP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>In vitro transporter inhibition was assessed using HEK293 cells expressing human dopamine (DA), norepinephrine, and serotonin transporter (DAT, NET, or SERT). In male rodents, locomotor activity was measured after i.p. (mice) or s.c. (rats) administration. In vivo microdialysis in rats quantified extracellular DA in the nucleus accumbens. Rewarding and reinforcing effects were evaluated using conditioned place preference (CPP) in mice and intravenous self-administration (IVSA) in rats under fixed-ratio and progressive-ratio schedules.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>In vitro assays revealed that 4-F-3-Me-\u03b1-PVP acts as a potent DAT and NET inhibitor, with additional, though weaker, activity at SERT. In vivo, 4-F-3-Me-\u03b1-PVP significantly increased locomotor activity in male rodents (10 and 30\u2009mg\/kg in mice; 3\u2009mg\/kg in rats). Importantly, 4-F-3-Me-\u03b1-PVP also increased extracellular DA levels in the rat nucleus accumbens (3\u2009mg\/kg, s.c.), pointing to its potential for abuse. Behavioral assays further demonstrated rewarding and reinforcing effects in rodents, with significant CPP in mice at all doses tested and dose-dependent IVSA in rats observed under both fixed-ratio and progressive-ratio schedules.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Collectively, these findings indicate that 4-F-3-Me-\u03b1-PVP possesses substantial psychostimulant and abuse-related effects in rodents, underscoring the need for regulatory vigilance and continued investigation into emerging synthetic cathinones.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/02698811261430492","type":"journal-article","created":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T01:03:02Z","timestamp":1773450182000},"page":"1506-1518","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Pharmacological characterization of 4-F-3-Me-\u03b1-PVP: A novel synthetic cathinone with psychostimulant effects and abuse liability in rodents"],"prefix":"10.1177","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9791-249X","authenticated-orcid":false,"given":"N\u00faria","family":"Nadal-Gratac\u00f3s","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Toxicology and Therapeutic Chemistry, Pharmacology Section, Faculty of Pharmacy and Food Science and Institute of Biomedicine (IBUB), Universitat de Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Pain","sequence":"additional","affiliation":[{"name":"Laboratoire de Neurosciences Exp\u00e9rimentales et Cliniques, Universit\u00e9 de Poitiers, INSERM, France"},{"name":"Service de Pharmacologie Clinique et Vigilances, CHU de Poitiers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Mata","sequence":"additional","affiliation":[{"name":"Chemical Reactions for Innovative Solutions (CRISOL), IQS School of Engineering, Universitat Ramon Llull, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pol","family":"Puigseslloses","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Toxicology and Therapeutic Chemistry, Pharmacology Section, Faculty of Pharmacy and Food Science and Institute of Biomedicine (IBUB), Universitat de Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgane","family":"De Macedo","sequence":"additional","affiliation":[{"name":"Laboratoire de Neurosciences Exp\u00e9rimentales et Cliniques, Universit\u00e9 de Poitiers, INSERM, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Lardeux","sequence":"additional","affiliation":[{"name":"Laboratoire de Neurosciences Exp\u00e9rimentales et Cliniques, Universit\u00e9 de Poitiers, INSERM, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fu-Hua","family":"Wang","sequence":"additional","affiliation":[{"name":"Pronexus Analytical AB, Bromma, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liselott","family":"K\u00e4llsten","sequence":"additional","affiliation":[{"name":"Pronexus Analytical AB, Bromma, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Pubill","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Toxicology and Therapeutic Chemistry, Pharmacology Section, Faculty of Pharmacy and Food Science and Institute of Biomedicine (IBUB), Universitat de Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Berzosa","sequence":"additional","affiliation":[{"name":"Chemical Reactions for Innovative Solutions (CRISOL), IQS School of Engineering, Universitat Ramon Llull, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Kehr","sequence":"additional","affiliation":[{"name":"Pronexus Analytical AB, Bromma, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0664-5964","authenticated-orcid":false,"given":"Marcello","family":"Solinas","sequence":"additional","affiliation":[{"name":"Laboratoire de Neurosciences Exp\u00e9rimentales et Cliniques, Universit\u00e9 de Poitiers, INSERM, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5078-366X","authenticated-orcid":false,"given":"Elena","family":"Escubedo","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Toxicology and Therapeutic Chemistry, Pharmacology Section, Faculty of Pharmacy and Food Science and Institute of Biomedicine (IBUB), Universitat de Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Camarasa","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Toxicology and Therapeutic Chemistry, Pharmacology Section, Faculty of Pharmacy and Food Science and Institute of Biomedicine (IBUB), Universitat de Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8904-7398","authenticated-orcid":false,"given":"Raul","family":"L\u00f3pez-Arnau","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Toxicology and Therapeutic Chemistry, Pharmacology Section, Faculty of Pharmacy and Food Science and Institute of Biomedicine (IBUB), Universitat de Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,3,13]]},"reference":[{"key":"e_1_3_2_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2013.04.003"},{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-015-3944-8"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002130000569"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2012.204"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/164_2018_178"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.3109\/15563650.2015.1089576"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1080\/15563650.2016.1190979"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.13030"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2015.01.003"},{"key":"e_1_3_2_11_1","unstructured":"DEA (2015) Established aggregate production quotas for schedule I and II controlled substances and assessment of annual needs for the list I chemicals ephedrine pseudoephedrine and phenylpropanolamine for 2016. Available at: https:\/\/www.federalregister.gov\/documents\/2015\/10\/06\/2015-25373\/established-aggregate-production-quotas-for-schedule-i-and-ii-controlled-substances-and-assessment (accessed 22 September 2025)."},{"key":"e_1_3_2_12_1","unstructured":"DEA (2022) Schedules of controlled substances: Placement of N-ethylhexedrone alpha-pyrrolidinohexanophenone 4-methyl-alpha-ethylaminopentiophenone 4\u2032-methyl-alpha-pyrrolidinohexiophenone alpha-pyrrolidinoheptaphenone and 4\u2032-chloro-alpha-pyrrolidinovalerophenone in schedule I. Available at: https:\/\/www.federalregister.gov\/documents\/2022\/06\/01\/2022-11740\/schedules-of-controlled-substances-placement-of-n-ethylhexedrone-alpha-pyrrolidinohexanophenone?utm_source=chatgpt.com (accessed 22 September 2025)."},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.85.14.5274"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2018.01.020"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2021.108475"},{"key":"e_1_3_2_16_1","volume-title":"EMCDDA-Europol joint report on a new psychoactive substance MDPV (3,4-methylenedioxypyrovalerone)","author":"European Monitoring Centre for Drugs and Drug Addction (EMCDDA) \u2013 Europol","year":"2014","unstructured":"European Monitoring Centre for Drugs and Drug Addction (EMCDDA) \u2013 Europol (2014) EMCDDA-Europol joint report on a new psychoactive substance MDPV (3,4-methylenedioxypyrovalerone), Joint Reports Publications Office of the European Union, Luxembourg."},{"key":"e_1_3_2_17_1","unstructured":"European Monitoring Centre for Drugs and Drug Addction (EMCDDA)-Europol (2015) EMCDDA-Europol Joint Report on a new psychoactive substance: 1-phenyl-2-(1-pyrrolidinyl)-1-pentanone (\u03b1-PVP) Join Reports Publications Office of the European Union Luxembourg."},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tvjl.2017.12.017"},{"key":"e_1_3_2_19_1","unstructured":"Food and Drug Administration (FDA) (2005) Guidance for industry: Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers pharmacology and toxicology guidance for industry estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. Available at: http:\/\/www.fda.gov\/cder\/guidance\/index.htm (accessed 15 October 2025)."},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-017-4562-4"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12640-017-9769-y"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainresbull.2016.04.011"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/0361-9230(87)90047-5"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/bkac003"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/0471142735.im0112s82"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2006.08.031"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2011.01499.x"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22158277"},{"key":"e_1_3_2_29_1","volume-title":"1-(3\u2019,4\u2019-Methylenedioxy-Phenyl)-2-Pyrrolidino-Alkanones-(1). 3478050A","author":"Koppe H","year":"1969","unstructured":"Koppe H, Ludwig G, Zeile K (1969) 1-(3\u2019,4\u2019-Methylenedioxy-Phenyl)-2-Pyrrolidino-Alkanones-(1). 3478050A. United States Patent and Trademark Office."},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11419-022-00639-5"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-018-5052-z"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/bks136"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm050797a"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyu038"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.749429"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23042226"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1021\/acschemneuro.2c00772"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsptsci.4c00299"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2025.110425"},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.4103\/0976-0105.177703"},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/7854_2016_18"},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.1124\/pr.112.007419"},{"key":"e_1_3_2_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2019.172762"},{"issue":"6","key":"e_1_3_2_44_1","article-title":"Persistent binding at dopamine transporters determines sustained psychostimulant effects","volume":"120","author":"Niello M","year":"2023","unstructured":"Niello M, Sideromenos S, Gradisch R, et al. (2023) Persistent binding at dopamine transporters determines sustained psychostimulant effects. Proceedings of the National Academy of Sciences of the United States of America 120(6): e2114204120.","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"e_1_3_2_45_1","unstructured":"NMS Labs (2020) 4-Fluoro-3-Methyl-Alpha-PVP. Available at: https:\/\/www.cfsre.org\/images\/monographs\/4-Fluoro-3-Methyl-Alpha-PVP_120120_NMSLabs_Report.pdf (accessed 7 April 2025)."},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2026.178570"},{"key":"e_1_3_2_47_1","first-page":"170","volume-title":"The Rat Brain in Stereotaxic Coordinates Seventh Edition","author":"Paxinos G","year":"2014","unstructured":"Paxinos G, Watson C (2014) The Rat Brain in Stereotaxic Coordinates Seventh Edition. Elsevier Academic Press, p. 170."},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.1113\/EP088870"},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.1096\/fj.07-9574LSF"},{"key":"e_1_3_2_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/0165-0270(95)00153-0"},{"key":"e_1_3_2_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2014.12.012"},{"key":"e_1_3_2_52_1","doi-asserted-by":"publisher","DOI":"10.3390\/cryst13060934"},{"key":"e_1_3_2_53_1","unstructured":"Seeger E (1966) Compositions and methods for stimulating the central nervous system and in-creasing the blood pressure. US Patent 3287217."},{"key":"e_1_3_2_54_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2012.02145.x"},{"key":"e_1_3_2_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/0166-4328(94)90008-6"},{"key":"e_1_3_2_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2014.11.006"},{"key":"e_1_3_2_57_1","doi-asserted-by":"publisher","DOI":"10.3109\/15563650.2011.590812"},{"key":"e_1_3_2_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2021.108820"},{"key":"e_1_3_2_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.108910"},{"key":"e_1_3_2_60_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1369-1600.2007.00070.x"},{"key":"e_1_3_2_61_1","unstructured":"United Nations Office on Drugs and Crime (UNODC) (2024) World Drug Report 2024 - Drug market patterns and trends. Geneva Switzerland. Available at: https:\/\/www.unodc.org\/unodc\/en\/data-and-analysis\/wdr2024-drug-market-trends.html (accessed 7 April 2025)."},{"key":"e_1_3_2_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/0091-3057(94)90132-5"},{"key":"e_1_3_2_63_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrn.2017.130"},{"issue":"2","key":"e_1_3_2_64_1","first-page":"144","article-title":"Structural analysis and characterization of 4-F-\u03b1-PVP analog 4-F-3-methyl-\u03b1-PVP hydrochloride","volume":"39","author":"Wang HY","year":"2023","unstructured":"Wang HY, Wu J, Zhang Q, et al. (2023) Structural analysis and characterization of 4-F-\u03b1-PVP analog 4-F-3-methyl-\u03b1-PVP hydrochloride. Journal of Forensic Medicine 39(2): 144\u2013150.","journal-title":"Journal of Forensic Medicine"},{"key":"e_1_3_2_65_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12640-020-00227-8"},{"key":"e_1_3_2_66_1","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/bkw029"},{"key":"e_1_3_2_67_1","doi-asserted-by":"publisher","DOI":"10.1111\/1556-4029.12260"}],"container-title":["Journal of Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811261430492","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/02698811261430492","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811261430492","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T23:27:13Z","timestamp":1787182033000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/02698811261430492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,13]]},"references-count":66,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1177\/02698811261430492"],"URL":"https:\/\/doi.org\/10.1177\/02698811261430492","relation":{},"ISSN":["0269-8811","1461-7285"],"issn-type":[{"value":"0269-8811","type":"print"},{"value":"1461-7285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,13]]}}}